Skip to main content
[Preprint]. 2024 Nov 22:2024.11.21.624760. [Version 1] doi: 10.1101/2024.11.21.624760

Figure 4. Antigenic characterization of ML designed LASV GPC constructs.

Figure 4.

(A) Protein yield of 24 lead designs (with high pLDDT confidence predictions). (B) Fold change compared to GPC-CysR4-I53A for designs from panel A. (C) Antigenic profile of all 24 designs with a panel of conformation specific monoclonal antibodies.